Table 1.

Characteristics of DCIS cases according to collagen alignment and syndecan-1 staining around DCIS lesions, WISC study

Collagen alignment (n = 227)Syndecan-1 staining (n = 125)
CharacteristicsaTotal no.TACS (%)PbTotal no.Average staining signalPc
Age
 20–497244.4390.0129
 50–6410550.5540.0158
 65–745056.00.45320.01390.58
Tumor grade
 Low4646.7240.0148
 Intermediate8851.7450.0145
 High9349.60.71560.01400.57
Comedo necrosis
 Absent10541.9530.0128
 Present12256.60.03720.01550.24
Multifocality
 Absent7351.2440.0132
 Present15449.10.74810.01500.32
Method of detection
 Symptomatic3563.0210.0187
 Mammography19247.40.091040.01350.34
ER status
 Negative3574.3220.0227
 Positive19245.30.0021030.01260.07
PR status
 Negative7760.7390.0173
 Positive15044.20.02860.01310.22
HER2 status
 Negative10245.3450.0119
 Equivocal6338.8420.0131
 Positive6268.20.002380.01870.18
Treatment
 BCS4255.3190.0127
 BCS with radiation9843.9550.0142
 Mastectomy8753.70.28510.01530.54
Endocrine therapy
 No16451.6870.0141
 Yes6345.20.43380.01500.56
  • Abbreviations: BCS, breast conserving surgery; TACS, tumor-associated collagen signature.

  • aAt baseline. Missing data were imputed for grade (n = 141), multifocality (n = 20), method of detection (n = 1), ER status (n = 1), PR status (n = 3), HER2 status (n = 5), surgical treatment (n = 66), and endocrine therapy (n = 60). Zero cases were missing data for age or comedo necrosis.

  • bFrom χ2 tests of the association between patient characteristics and TACS present in at least one DCIS duct.

  • cFrom two-sided t tests using ANOVA.